ABSTRACT
PURPOSE: Telomerase is known to play a role of adding repetitive parts to chromosomal ending and to be involved in carcinogenic process through cell immortalization. The purpose of this study is to evaluate that restraining of telomerase activation can have killing effect on cancer cell and enhance susceptibility of cancer cells to anticancer substance. METHODS: The killing effect on melanoma cells was studied by using recombinant adenovirus that makes it possible to inhibit telomerase from getting activated, with such targets as two types of melanoma cell lines. This recombinant adenovirus was used combined with cisplatin, one of the most representative anticancer medicine to evaluate enhancement in susceptibility of cancer cells to anticancer substance. RESULTS: From the result of cytotoxic assay, it is found that melanoma cells have much resistance to cisplatin on the whole. In the case of using Ad-OA of recombinant virus alone, killing effect on melanoma cells was insignificant. On the other hand, when Ad-OA was used in combination with cisplatin, susceptibility of melanoma cell lines to cisplatin was enhanced. CONCLUSIONS: Ad-OA, recombinant adenovirus, could be used as a supplementary medicine in the targeted cancer gene therapy against cancer cell lines resistant to cisplatin.